ReviewTheScientificWorldJournal2013
Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy.
Review in TheScientificWorldJournal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Long-Term Intensive Lifestyle Intervention Promotes Improvement of Stage III Diabetic Nephropathy.Medical science monitor : international medical journal of experimental and clinical research · 2019Trial
- Exercise in Diabetic Nephropathy: Protective Effects and Molecular Mechanism.International journal of molecular sciences · 2024Review
- Pectin-Lyase-Modified Ginseng Extract and Ginsenoside Rd Inhibits High Glucose-Induced ROS Production in Mesangial Cells and Prevents Renal Dysfunction in db/db Mice.Molecules (Basel, Switzerland) · 2021Article
- Effects of Dexmedetomidine on the RhoA /ROCK/ Nox4 Signaling Pathway in Renal Fibrosis of Diabetic Rats.Open medicine (Warsaw, Poland) · 2019Article
- Renoprotective effect of Zhenwu decoction against renal fibrosis by regulation of oxidative damage and energy metabolism disorder.Scientific reports · 2018Article
- Rhein lysinate protects renal function in diabetic nephropathy of KK/HlJ mice.Experimental and therapeutic medicine · 2017Article
- Disease-syndrome combination modeling: metabolomic strategy for the pathogenesis of chronic kidney disease.Scientific reports · 2017Article
- New molecular insights in diabetic nephropathy.International urology and nephrology · 2016Review
- Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes?Stem cells international · 2016Review
- Diabetic nephropathy: What does the future hold?International urology and nephrology · 2016Review
- Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Journal of clinical medicine · 2015Review
- Autophagy-Lysosome Pathway in Renal Tubular Epithelial Cells Is Disrupted by Advanced Glycation End Products in Diabetic Nephropathy.The Journal of biological chemistry · 2015Article
- Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model.American journal of physiology. Endocrinology and metabolism · 2015Article
- Article
- Vitamin D therapy in diabetic kidney disease.Journal of nephropharmacology · 2014Article
- Angiotensin I converting enzyme inhibitory peptides obtained after in vitro hydrolysis of pea (Pisum sativum var. Bajka) globulins.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. However, current treatments remain suboptimal. Many factors, such as genetic and nongenetic promoters, hypertension, hyperglycemia, the accumulation of advanced glycation end products (AGEs), dyslipidemia, and albuminuria/proteinuria itself, influence the progression of this disease. It is important to determine the molecular mechanisms and treatment of this disease. The development of diabetes results in the formation of AGEs, oxidative stress, and the activation of the renin-angiotensin-aldosterone system (RAAS) within the kidney, which promotes progressive inflammation and fibrosis, leading to DN and declining renal function. A number of novel therapies have also been tested in the experimental diabetic model, including exercise, inhibitors of the RAAS (angiotensin type 1 receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors), inhibitors of AGE (pyridoxamine), peroxisome proliferator-activated receptor (PPAR) γ agonists (pioglitazone), inhibitors of lipid accumulation (statins and eicosapentaenoic acid (EPA)), and the vitamin D analogues. This review summarizes the advances in knowledge gained from our studies and therapeutic interventions that may prevent this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.